CDNF Safe in Advanced Parkinson’s, Trial Results Show

CDNF Safe in Advanced Parkinson’s, Trial Results Show
Treatment with cerebral dopamine neurotrophic factor (CDNF), developed by Herantis Pharma, was safe and well-tolerated among patients with advanced-stage Parkinson’s disease, according to topline results from a Phase1/2 clinical trial. The therapy also showed promise in measures of dopaminergic function in some patients. CDNF is based on a protein naturally found in the blood and cerebrospinal fluid (CSF), the liquid ... read more
Source: Parkinson’s News TodayPublished on 2020-02-27By Patricia Inacio, PhD

Related Articles:

  • Patient Treatment Completed in Phase 1/2 Trial Testing Therapy Candidate CDNF in Parkinson’s Disease January 3, 2020 Patient treatment has been completed in a Phase 1/2 clinical trial testing cerebral dopamine neurotrophic factor (CDNF) for Parkinson’s disease, Herantis Pharma has announced. The trial (NCT03295786) is testing the safety and tolerability of CDNF in 17 patients with advanced Parkinson’s disease. Of these patients, 15 completed the main study and will advance into a six-month extension study where they…
  • Herantis Pharma: Phase 1/2 CDNF Topline Results February 26, 2020 We are delighted that Finnish-based Herantis Pharma Plc have announced that their ongoing Phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint of safety and tolerability. In pre-clinical studies, CDNF has been shown to have a protective impact on pathways involved in Parkinson’s, preventing neurons from…
  • Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial February 25, 2020 HELSINKI, Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses as measured by PET imaging in some patients. Results from the second part of trial, in which all...
  • Herantis’s Parkinson’s Therapy Passes Preliminary Trial Safety Evaluation February 20, 2018 An independent review board has found Herantis Pharma’s Parkinson’s therapy safe, paving the way for a Phase 1/2 clinical trial in Sweden to continue. The board based its decision on the safety results seen in the first few patients treated with cerebral dopamine neurotrophic factor, or CDNF, at Karolinska University Hospital in Stockholm. Its findings mean Herantis can recruit patients at two other study sites — Helsinki University Hospital…
  • Herantis Announces Non-Invasive Treatment Plan of CDNF July 12, 2018 Herantis Pharma has announced the initiation of a 'non-invasive' CDNF (cerebral dopamine neurotrophic factor) development programme to broaden the application of CDNF in treating Parkinson's. Naturally present in the human blood circulation and cerebrospinal fluid, CDNF is a potent neuroprotective factor that promotes neuronal survival. In preclinical proof-of-concept studies CDNF has demonstrated beneficial effects in Parkinson's alleviating both motor and…
  • Herantis Announces Non-Invasive Treatment Plan of CDNF July 12, 2018 Herantis Pharma has announced the initiation of a 'non-invasive' CDNF (cerebral dopamine neurotrophic factor) development programme to broaden the application of CDNF in treating Parkinson's. Naturally present in the human blood circulation and cerebrospinal fluid, CDNF is a potent neuroprotective factor that promotes neuronal survival. In preclinical proof-of-concept studies CDNF has demonstrated beneficial effects in Parkinson's alleviating both motor and…
  • Herantis Pharma Is Recruiting Patients for Clinical Trial of CDNF as Parkinson’s Treatment October 2, 2017 Herantis Pharma has started the first clinical trial of cerebral dopamine neurotrophic factor (CDNF) as a potential treatment for Parkinson’s disease. The first patient in the Phase 1/2 clinical trial has enrolled at the Karolinska University Hospital in Stockholm. The study will also involve another hospital in Sweden and one in Finland. Herantis is developing CDNF as a treatment for both Parkinson’s…
  • Herantis Announces New Program to Develop Non-Invasive CDNF for Parkinson’s Treatment July 10, 2018 Herantis Pharma is launching a development program for non-invasive cerebral dopamine neurotrophic factor (CDNF) as a treatment candidate for patients with Parkinson’s disease, the company recently announced. Currently, the investigational treatment needs to be administered directly into the brain using an implanted delivery system suited for Parkinson’s patients. Under the new program, Herantis will seek new methods of delivering the therapy to…
  • Herantis Pharma begins Recruitment for CDNF Trial March 5, 2018 Herantis Pharma Plc's first clinical study for people with Parkinson's with the company's investigational product CDNF has proceeded to its first CDNF safety assessment study.  CDNF is a novel drug candidate for the treatment of neurodegenerative diseases including Parkinson's. CDNF is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties. It is patented internationally by Herantis. Recruitment…
  • Herantis Pharma begins Recruitment for CDNF Trial March 5, 2018 Herantis Pharma Plc's first clinical study for people with Parkinson's with the company's investigational product CDNF has proceeded to its first CDNF safety assessment study.  CDNF is a novel drug candidate for the treatment of neurodegenerative diseases including Parkinson's. CDNF is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties. It is patented internationally by Herantis. Recruitment…
  • Herantis Creates Video to Show How Its Parkinson’s Therapy Works April 9, 2018 Herantis Pharma has created an educational video about the way its Parkinson’s treatment CDNF works. The explainer comes as the company has begun recruiting patients for a Phase 1/2 clinical trial (NCT03295786) of the potential therapy. Hallmarks of Parkinson’s include damage to dopamine-producing nerve cells in a brain area called the substantia nigra, toxic accumulation of alpha-synuclein protein clumps in nerve cells, and chronic brain inflammation.…
  • Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. June 28, 2019 Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. Front Neurosci. 2019;13:590 Authors: Albert K, Renko JM, Mätlik K, Airavaara M, Voutilainen MH Abstract Cerebral dopamine neurotrophic factor (CDNF) has shown therapeutic potential in rodent and non-human primate models of Parkinson's disease by protecting the dopamine neurons from degeneration…
  • Increased Serum Levels of Mesencephalic Astrocyte-Derived Neurotrophic Factor in Subjects With Parkinson's Disease. September 27, 2019 Related ArticlesIncreased Serum Levels of Mesencephalic Astrocyte-Derived Neurotrophic Factor in Subjects With Parkinson's Disease. Front Neurosci. 2019;13:929 Authors: Galli E, Planken A, Kadastik-Eerme L, Saarma M, Taba P, Lindholm P Abstract Background: Mesencephalic astrocyte-derived neurotrophic factor (MANF) and cerebral dopamine neurotrophic factor (CDNF) promote the survival of midbrain dopamine neurons in animal models of Parkinson's disease (PD). However, little is…
  • Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial - GlobeNewswire September 26, 2019 Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial  GlobeNewswire
  • CDNF Protein Therapy in Parkinson's Disease. April 6, 2019 Related ArticlesCDNF Protein Therapy in Parkinson's Disease. Cell Transplant. 2019 Apr 04;:963689719840290 Authors: Huttunen HJ, Saarma M Abstract Neurotrophic factors (NTF) are a subgroup of growth factors that promote survival and differentiation of neurons. Due to their neuroprotective and neurorestorative properties, their therapeutic potential has been tested in various neurodegenerative diseases. Bioavailability of NTFs in the target tissue remains a…
  • The Phase 1/2 CDNF topline results February 25, 2020       Neurotrophic factors are naturally occuring proteins that help to keep neurons alive, provide a supportive environment, and encourage growth. For a long time, researchers have been exploring methods of utilising the power of neurotrophic factors in regenerative strategies for neurodegenerative conditions, like Parkinson’s. Today, the biotech firm Herantis Pharma announced topline results of their Phase 1/2 clinical…
  • Effect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease. April 9, 2019 Related ArticlesEffect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease. EXCLI J. 2019;18:139-153 Authors: Nasrolahi A, Mahmoudi J, Karimipour M, Akbarzadeh A, Sadigh-Eteghad S, Salehi R, Farajdokht F, Farhoudi M Abstract This study investigated the ability of intra-subventricular zone (SVZ) administration of cerebral dopamine neurotrophic factor (CDNF) on neural progenitor…
  • One-year Results in 2 Given Gene Therapy at Low Dose Showing Promise, Axovant Reports January 14, 2020 Two Parkinson’s patients treated with AXO-Lenti-PD, an investigative gene therapy, in an ongoing clinical trial continue to show improvement 12 months later, Axovant, the therapy’s developer, said in a release. These findings at one year after treatment are important because this timepoint allows for a better assessment of therapy durability, and a more assured differentiation between placebo effects and therapeutic response,…
  • Phase 2 Trial Testing Leukemia Treatment, Nilotinib, in Range of Parkinson’s Patients March 5, 2018 People with Parkinson’s disease are being recruited for a new clinical trial testing nilotinib, an FDA-approved leukemia treatment, in a range of patients. The two-part Phase 2 trial (NCT03205488), called NILO-PD, is a randomized, double-blind, and placebo-controlled study taking place at 25 sites across the U.S. Part one will evaluate the safety and tolerability of different dosing levels of oral nilotinib (150 mg or…
  • Prasinezumab Fails to Slow Symptom Worsening in Parkinson’s, But Shows Other Signs of Effectiveness, Trial Finds April 24, 2020 Prasinezumab (PRX002/RG7935), an antibody designed to eliminate the toxic clumps of alpha-synuclein in Parkinson’s disease patients, did not lessen the progression of motor and non-motor symptoms over one year, compared with a placebo, findings from a Phase 2 clinical trial show. While the results mean that the PASADENA study (NCT03100149) did not achieve its primary goal, Roche — which is developing…